PetCaseFinder

Peer-reviewed veterinary case report

Calotropis procera plant extract kills dog mammary tumor and bone

By Rabelo, Ana CarolinaSilveira et al.·Published in Research in veterinary science·2021·Faculty of Veterinary Medicine and Animal Science, Brazil·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Calotropis procera (Aiton) Dryand (Apocynaceae) as an anti-cancer agent against canine mammary tumor and osteosarcoma cells.

Species:
dog

Plain-English summary

A study found that an extract from the Calotropis procera plant showed promise as a treatment for dogs with cancer, specifically those with mammary tumors and osteosarcoma (a type of bone cancer). The extract was tested in the lab and was able to reduce the growth of cancer cells without harming normal skin cells. It worked by triggering cell death in the cancer cells and slowing down their ability to multiply. This research suggests that Calotropis procera could be a potential option for treating these types of cancer in dogs, but more studies are needed to confirm its effectiveness in real-life cases.

People also search for: dog cancer treatment options · Calotropis procera for canine tumors · osteosarcoma in dogs treatment

Abstract

Our goal was to evaluate phytochemical characterization and the antitumor potential of Calotropis procera. The phytochemical constitution of the crude extract (CE) revealed the presence of flavonoids, glycosides and cardenolide. The MTT assay was used to evaluate the cytotoxicity of CE, methanolic (MF) and ethyl acetate fractions (EAF) of C. procera in canine osteosarcoma cells (OST), canine mammary tumor (CMT), and canine skin fibroblasts (non-tumor cell). Doxorubicin was also used as a positive control. Results showed that CE, MF and EAF promoted a decrease in the viability of OST and CMT cells and did not alter the fibroblasts viability. C. procera also decreased the number of cells, corroborating to the decrease in proliferation and the cell cycle arrest in the G0/G1 phase. It was also evaluated the cell morphology by light and fluorescence microscopy, being demonstrated a reduction in cytoplasmic and cell rounding characteristic of programmed cell death. Moreover, flow cytometry data demonstrated that CE treatment promoted increase of caspase-3 and p53, showing that the cell death was activated in OST cells. In addition, there was a decrease in CD31, VEGF, osteopontin and TGF-β after CE treatment, suggesting that CE exerts its antitumor effect by reducing angiogenesis and tumor progression in OST cells. Moreover, CMT cells showed a reduction in PCNA after treatment with MF and CE. Analyzing the data together, C. procera, especially CE, showed an antitumor potential in both OST and CMT cells, encouraging us to continue investigating its use in cancer therapy.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34119813/